Gelonghui Chenxin Pharmaceutical Co., Ltd. (603367.SH) announced that it has received the "Drug Registration Certificate" of Voglibose tablets (Certificate No.: 2023S00722) and the "Drug Registration Certificate" of Carbetocin injection (Certificate No.: 2023S00726) approved by the State Drug Administration. Voglibose tablet is an oral hypoglycemic drug. As an α-glucosidase inhibitor, it inhibits the disaccharide hydrolase (α-glucosidase) that decomposes disaccharides into monosaccharides in the intestine, thus delaying the digestion and absorption of sugars, thereby improving postprandial hyperglycemia.
辰欣药业(603367.SH)：伏格列波糖片获得药品注册证书
Chenxin Pharmaceutical (603367.SH): Volglebose tablets obtained a drug registration certificate
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.